Next-generation genomic analysis for next-generation medicine
Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount of useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
SeqOne’s mission: making genomic medicine accessible to all
Thanks to NGS, the cost of sequencing has dropped from billions of dollars twenty years ago to a few hundred dollars per patient today. NGS not only reduces costs but also provides much more detailed raw data that can provide valuable insights that can improve treatment options. Sadly, analysing this richer information is difficult and costly and beyond the capabilities of traditional genomic analysis software. SeqOne’s mission is to provide advanced genomic analysis tools that make it possible to analyse NGS data cost-effectively at scale and so to ensure that the benefits of genomic medicine are available to everyone.
SeqOne, the company
SeqOne started as the dream of two childhood friends Nicolas Philippe and Guillaume Buwalda who imagined a better way to analyse genomic data in healthcare. After working on the concept for several years as a research project, they attracted the attention of two regional technology incubators (BIC and LRI) as well as a technology transfer agency (SATT AxLR). More recently, venture capital funds, Elaia and IRDI/SORIDEC in conjunction with the BPI France invested three million (€3M) in the company to accelerate its development.
Today, SeqOne is a startup based in Montpellier in the south of France. The company serves healthcare customers in both the private and public sectors. Its proprietary platform optimised for high-performance genomic analysis manages thousands of patients. The platform also boasts an ecosystem of specialised bioinformatic developers who provide tools designed to answer specific medical challenges.
SeqOne's team has over twenty years of experience in analysing Next Generation Sequencing (NGS) genomic data
Author of the globally recognised CRAC bioinformatic software, Nicolas has published numerous academic papers bioinformatics and RNA-Seq applications.
Specialised in secure, high performance computer systems, notably in banking, Guillaume has designed SeqOne's platform with performance, security and scalability in mind.
A French start-up harnesses the power of the latest generation genomic sequencers to dramatically increase COVID 19 testing capacity
SeqOne Genomics, a start-up specialized in genomic analysis software, is partnering with leading medical testing labs to develop an approach that delivers up to 100 times more COVID 19 tests per machine thanks to NGS sequencers. Montpellier: May 1st, 2020: Epidemiological experts agree that the key to successfully managing the COVID 19 pandemic is a […]Read more See all
For press or investor related queries, please contact:
+ 33 (0)6 03 24 57 56